LLY.DE लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 21:05):

Stats
आज की मात्रा	7 966.00
औसत मात्रा	6 577.00
बाजार मूल्य	648.75B
EPS	€0 ( 2024-04-30 )
Last Dividend	€1.130 ( 2023-08-14 )
Next Dividend	€0 ( N/A )
P/E	107.50
ATR14	€0.984 (0.14%)

मात्रा सहसंबंध

लंबा: 0.00 (neutral)

छोटा: -0.28 (neutral)

Signal:(52.277) Neutral

Eli Lilly and Co सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Eli Lilly and Co सहसंबंध - मुद्रा/वस्त्र

0.62
( weak )

0.58
( weak )

0.67
( moderate )

0.51
( weak )

0.60
( weak )

-0.59
( weak negative )

Eli Lilly and Co वित्तीय

Annual	2023
राजस्व:	€34.12B
सकल लाभ:	€27.04B (79.25 %)
EPS:	€5.82

FY	2023
राजस्व:	€34.12B
सकल लाभ:	€27.04B (79.25 %)
EPS:	€5.82

FY	2022
राजस्व:	€28.54B
सकल लाभ:	€21.91B (76.77 %)
EPS:	€6.93

FY	2021
राजस्व:	€28.32B
सकल लाभ:	€21.01B (74.18 %)
EPS:	€5.83

Financial Reports:

No articles found.

Eli Lilly and Co Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0.980 (N/A)	€0.980 (N/A)	€1.130 (N/A)	€1.130 (N/A)	€1.130 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Eli Lilly and Co Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 7.36 - good (73.60%) | Divividend Growth Potential Score: 6.18 - Stable (23.51%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.490	2009-05-13
Last Dividend	€1.130	2023-08-14
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	41	--
Total Paid Out	€27.35	--
Avg. Dividend % Per Year	0.00%	--
Score	3.94	--
Div. Sustainability Score	7.36
Div.Growth Potential Score	6.18
Div. Directional Score	6.77	--

Next Divdend (Est)
(2024-09-05)

€1.166 Estimate 20.00 %

Dividend Stability

0.53 Average

Dividend Score

3.94

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
WAC.DE	Ex Dividend Junior	2023-05-29	Annually	0.00%
ENI.F	Ex Dividend Knight	2023-11-20	Semi-Annually	0.00%
OPC.DE	Ex Dividend Knight	2023-09-07	Quarterly	0.00%
AEC1.DE	Ex Dividend Knight	2023-07-06	Quarterly	0.00%
GSC1.DE	Ex Dividend Knight	2023-06-13	Annually	0.00%
RNT.F	Ex Dividend Junior	2023-09-13	Annually	0.00%
BMT.DE	Ex Dividend Junior	2023-09-28	Quarterly	0.00%
IVU.DE	Ex Dividend Junior	2023-05-26	Sporadic	0.00%
TII.DE	Ex Dividend Knight	2023-07-28	Quarterly	0.00%
CTP2.DE	Ex Dividend Knight	2023-10-03	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.171	1.500	6.58	9.88	[0 - 0.5]
returnOnAssetsTTM	0.0960	1.200	6.80	8.16	[0 - 0.3]
returnOnEquityTTM	0.535	1.500	5.16	7.74	[0.1 - 1]
payoutRatioTTM	0.688	-1.000	3.12	-3.12	[0 - 1]
currentRatioTTM	1.354	0.800	8.23	6.58	[1 - 3]
quickRatioTTM	0.677	0.800	-0.721	-0.577	[0.8 - 2.5]
cashRatioTTM	0.132	1.500	-0.376	-0.564	[0.2 - 2]
debtRatioTTM	0.410	-1.500	3.17	-4.75	[0 - 0.6]
interestCoverageTTM	15.16	1.000	5.50	5.50	[3 - 30]
operatingCashFlowPerShareTTM	4.06	2.00	8.65	10.00	[0 - 30]
freeCashFlowPerShareTTM	-4.31	2.00	-2.15	-4.31	[0 - 20]
debtEquityRatioTTM	2.05	-1.500	1.817	-2.73	[0 - 2.5]
grossProfitMarginTTM	0.802	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.237	1.000	7.25	7.25	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.140	1.000	-0.332	-0.332	[0.2 - 2]
assetTurnoverTTM	0.562	0.800	9.59	7.67	[0.5 - 2]
Total Score				7.36

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	108.28	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.535	2.50	6.89	7.74	[0.1 - 1.5]
freeCashFlowPerShareTTM	-4.31	2.00	-1.436	-4.31	[0 - 30]
dividendYielPercentageTTM	0.638	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.06	2.00	8.65	10.00	[0 - 30]
payoutRatioTTM	0.688	1.500	3.12	-3.12	[0 - 1]
pegRatioTTM	9.48	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.102	1.000	9.94	0	[0.1 - 0.5]
Total Score				6.18

Eli Lilly and Co

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.